What is HC Wainwright's Estimate for CADL Q2 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Candel Therapeutics in a research note issued on Monday, June 30th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Candel Therapeutics' FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.44) EPS.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.37.

Separately, Wall Street Zen upgraded shares of Candel Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $22.00.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock traded up $0.14 during midday trading on Wednesday, hitting $4.99. 913,753 shares of the company traded hands, compared to its average volume of 1,473,974. The firm's fifty day moving average price is $5.22 and its 200-day moving average price is $6.74. The stock has a market cap of $250.00 million, a price-to-earnings ratio of -3.72 and a beta of -0.91. Candel Therapeutics has a 12 month low of $3.79 and a 12 month high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.64 and a current ratio of 4.64.

Institutional Trading of Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in Candel Therapeutics by 17.0% during the 4th quarter. Rhumbline Advisers now owns 26,272 shares of the company's stock worth $228,000 after buying an additional 3,817 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Candel Therapeutics during the fourth quarter worth $329,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Candel Therapeutics by 11.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 52,190 shares of the company's stock worth $453,000 after purchasing an additional 5,413 shares during the period. Commonwealth Equity Services LLC bought a new stake in shares of Candel Therapeutics in the fourth quarter worth $357,000. Finally, Halter Ferguson Financial Inc. increased its holdings in Candel Therapeutics by 123.7% in the fourth quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company's stock valued at $5,914,000 after purchasing an additional 376,795 shares during the period. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.